GSK to roll out five vaccines by 2010

07/1/2005 | Forbes · Wall Street Journal, The

GlaxoSmithKline plans to put five major vaccines on the market in the next five years and estimates global sales for all could reach $18 billion annually. GSK plans to launch the cervical cancer vaccine Cervarix; Rotarix for rotavirus gastroenteritis; Streptorix, for pneumococcal disease; an improved flu vaccine; and a combination vaccine for meningitis. A company official described the vaccine field as an area of "explosive growth," and noted improvements in biologics have allowed development of vaccines that previously failed.

View Full Article in:

Forbes · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care